BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Oct 11, 2010
 |  BC Week In Review  |  Clinical News  |  Regulatory

Ebixa memantine regulatory update

The U.K.'s NICE issued an appraisal consultation document that would allow for the broadened use of 4 Alzheimer's disease (AD) drugs, including Ebixa memantine. The agency now recommends the NMDA receptor antagonist for moderate...

Read the full 157 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >